Cingulate Inc
CING5.230USD
+0.130+2.55%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
20.01MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cingulate Inc Unternehmen
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Unternehmensinformationen
BörsenkürzelCING
Name des UnternehmensCingulate Inc
IPO-datumOct 07, 2021
CEODr. Shane J. Schaffer, Pharm.D.
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeOct 07
Addresse1901 W. 47Th Place
StadtKANSAS CITY
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl66205
Telefon19139422300
Websitehttps://www.cingulate.com/
BörsenkürzelCING
IPO-datumOct 07, 2021
CEODr. Shane J. Schaffer, Pharm.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Matthew N. Brams, M.D.
Dr. Matthew N. Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Dr. Laurie A. Myers, Ph.D.
Dr. Laurie A. Myers, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Matthew N. Brams, M.D.
Dr. Matthew N. Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Werth Family Investment Associates LLC
1.90%
Commonwealth Financial Network
1.08%
Geode Capital Management, L.L.C.
0.59%
UBS Financial Services, Inc.
0.43%
The Vanguard Group, Inc.
0.21%
Other
95.79%
Aktionäre
Aktionäre
Anteil
Werth Family Investment Associates LLC
1.90%
Commonwealth Financial Network
1.08%
Geode Capital Management, L.L.C.
0.59%
UBS Financial Services, Inc.
0.43%
The Vanguard Group, Inc.
0.21%
Other
95.79%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
2.37%
Corporation
2.32%
Investment Advisor/Hedge Fund
0.70%
Research Firm
0.05%
Individual Investor
0.01%
Other
94.55%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
44
238.41K
5.46%
-49.05K
2025Q1
47
242.60K
6.03%
-49.04K
2024Q4
47
197.43K
6.15%
-35.64K
2024Q3
47
156.73K
4.97%
-40.96K
2024Q2
44
186.43K
34.55%
+67.80K
2024Q1
47
54.28K
18.74%
+25.73K
2023Q4
45
21.28K
29.79%
-7.47K
2023Q3
42
26.64K
41.94%
+1.78K
2023Q2
36
15.08K
30.98%
-2.19K
2023Q1
34
15.09K
32.03%
-921.00
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Werth Family Investment Associates LLC
97.99K
2.31%
--
--
Apr 14, 2025
Commonwealth Financial Network
55.52K
1.31%
+12.50K
+29.05%
Mar 31, 2025
Geode Capital Management, L.L.C.
30.40K
0.72%
+3.08K
+11.26%
Mar 31, 2025
UBS Financial Services, Inc.
22.12K
0.52%
+9.92K
+81.34%
Mar 31, 2025
The Vanguard Group, Inc.
10.76K
0.25%
+8.76K
+438.54%
Mar 31, 2025
Quantum Private Wealth, LLC
10.00K
0.24%
+10.00K
--
Mar 31, 2025
Alphamark Advisors, LLC
5.01K
0.12%
+5.00K
+50000.00%
Dec 31, 2024
Fountainhead Shrugged, LLC
3.37K
0.08%
--
--
Apr 14, 2025
BofA Global Research (US)
1.96K
0.05%
+2.00
+0.10%
Mar 31, 2025
Tower Research Capital LLC
433.00
0.01%
-331.00
-43.32%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
Datum
Art
Verhältnis
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
